Search

BioScience
Brexit
Careers
Consumer Trends & Insight
Corporate Reputation
Crisis
Culture
Digital Trends
Edelman 67
Employee Engagement
Energy
Entertainment
Financial
General
General Election
Government Affairs
Graduate Scheme
Health
Innovation
Media
News
Technology
Trust
Women In The World
Purpose
Influencer Marketing
Integrated Marketing
Digital Design
Brand Marketing
Healthcare
Film Production
Community Management
Media Relations
Experiential
Corporate Communications & Advisory
Brand Strategy
Energy

Search

30 June 2016

EU Referendum Result: Health

Brexit, Government Affairs, Health

The Brexit vote brings immediate uncertainty to the pharmaceutical industry, in terms of export (the EU accounts for 56% of UK pharma exports) and regulation – of intellectual property rights, clinical trials, quality standards, and drug and devices approvals. While individual countries do have approval systems in place, as well as country rules over pricing and reimbursement, pharmaceutical companies see the harmonisation of approvals afforded by the European Medicines Agency (EMA) as a means of containing costs.

Edelman has prepared a full briefing on the implications of Brexit for the Health sector, to read it please click here or see below.

For more information, please contact Ann Bartling on +44 20 3047 2164 or at ann.bartling@edelman.com.

Please update your browser.

This website requires Chrome, Firefox, Safari or Internet Explorer 9+